NVCR - Novocure gets green light to continue late-stage ovarian cancer trial

An independent data monitoring has recommended that a phase 3 trial of Novocure's (NASDAQ:NVCR) Tumor Treating Fields (TTFs) for ovarian cancer should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended that the trial continue to a final analysis. The primary endpoint of the INNOVATE-3 trial, which is examining TTFs in combination with paclitaxel for platinum-resistant ovarian cancer, is overall survival. Secondary endpoints include progression-free survival, objective response rate, and severity and frequency of adverse events. Read why Seeking Alpha contributor ONeil Trader considers Novocure (NVCR) a strong buy.

For further details see:

Novocure gets green light to continue late-stage ovarian cancer trial